MedTrace Logo

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

NCT00003552 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2024-03-04

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy plus peripheral stem cell transplantation in treating patients with metastatic melanoma.

Conditions

  • Stage IV Melanoma
  • Recurrent Melanoma

Interventions

DRUG

allogeneic lymphocytes

DRUG

anti-thymocyte globulin

DRUG

cyclophosphamide

DRUG

fludarabine

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Richard W. Childs · National Heart, Lung, and Blood Institute (NHLBI)

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-31
Completion
2002-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003552 on ClinicalTrials.gov